# Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

> **NCT01325428** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 26 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Afatinib once daily (OD)
- **DRUG:** Vinorelbine Weekly

## Key facts

- **NCT ID:** NCT01325428
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2016-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01325428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01325428, "Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01325428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*